Piflufolastat f-18 injection drugs (pylarify) from sofie CO.:1108959 [25-004297]
Ended Awarded Last action
- Contract number
- 75N90025F00021
- Awardee
-
Progenics Pharmaceuticals Inc. UEI YLYKVRPCTCR3 Part of Lantheus Holdings, Inc.
- Awarding agency
-
NIH Clinical Center
National Institutes of Health, Department of Health and Human Services
- Obligated
- $181,236
Award facts
- Contract value 100% obligated
- $181,236.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
- Place of performance
- North Billerica, Billerica, MA 01862, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Funding Only Action | -$8,311 | |
| Original award | $189,547 |
About this award
The NIH Clinical Center awarded a delivery order to Progenics Pharmaceuticals Inc. (a division of Lantheus Medical Imaging, Inc.) for piflufolastat F-18 injection drugs marketed as PYLARIFY, with a ceiling value of $181,236 and a completion date of March 13, 2026. This is a firm fixed-price contract with no set-aside designation, issued under the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB). The contract was modified to reduce the unit price for the supplied product, demonstrating price optimization within the established contract vehicle. The place of performance is located in North Billerica, Massachusetts.
PYLARIFY is a radioactive diagnostic imaging agent used in positron emission tomography (PET) scans to detect and localize prostate cancer. This delivery order supports the NIH Clinical Center's medical imaging programs and reflects the government's continued reliance on Lantheus Holdings subsidiaries for specialized radiopharmaceuticals. Progenics Pharmaceuticals maintains a significant federal contracting presence across multiple agencies, including the Department of Veterans Affairs and Defense Health Agency, with multiple blanket purchase agreements and indefinite delivery vehicles totaling hundreds of millions in potential value. This award represents a continuation of the company's role as a critical supplier of diagnostic imaging agents to federal healthcare providers.
Quick answers
Who was awarded contract 75N90025F00021?
75N90025F00021 was awarded to Progenics Pharmaceuticals Inc. by NIH Clinical Center (National Institutes of Health) on March 14, 2025.
How much is contract 75N90025F00021 worth?
The government has obligated $181,236 on 75N90025F00021.
Is contract 75N90025F00021 an order under another contract?
Yes. 75N90025F00021 is a delivery order under 36F79719D0170, a federal supply schedule, on Pharmaceuticals and Drugs (FSS-61-IB).
Was contract 75N90025F00021 competed?
The extent of competition for 75N90025F00021 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award